FDA Warning Letter to Fagron Sterile Services Cites Sterility Practice Deficiencies at 503B Facility
On May 12, 2026, FDA issued a warning letter to Fresenius Kabi Compounding, LLC dba Fagron Sterile Services (Canton, MA), a registered 503B outsourcing facility, citing "Adulterated Drug Products." Following an October–November 2025 inspection, FDA noted "serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk." The letter acknowledges a February 5, 2026 voluntary recall of various lots of products produced using certain IV bags, due to lack of sterility assurance.
What this means503B outsourcing facilities compound medications at scale for hospitals, clinics, and telehealth programs — FDA findings at one are a reminder to ask any provider which facility fills its prescriptions and what that facility’s FDA record looks like.
Source: FDA original ↗